Skip to content
RNAWiki

Carmustine

  • Prescription medicine
  • Given by a clinician
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Carmustine does in the body

Carmustine for injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.

From the FDA-approved label: The activity of GLIADEL Wafer is due to release of cytotoxic concentrations of carmustine, a DNA and RNA alkylating agent, into the tumor resection cavity. On exposure to the aqueous environment of the resection cavity, the anhydride bonds in the copolymer are hydrolyzed, releasing carmustine, carboxyphenoxypropane, and sebacic acid into the surrounding brain tissue.

Why people take it. Carmustine for injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · U68WG3173Y · read 2026-08-29

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 147 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

The study did not show it

Who was studied
NCT00002653
How many people
1000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

survival

The study did not show it

Who was studied
NCT00002548
How many people
899
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

The study did not show it

Who was studied
NCT00002599
How many people
750
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Overall Survival

The study did not show it

Who was studied
NCT03722355
How many people
712
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Overall Survival

The study did not show it

Who was studied
NCT00083551
How many people
668
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

The study did not show it

Who was studied
NCT00002772
How many people
602
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Carmustine for Injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors (1) Multiple myeloma-in combination with prednisone (1) Relapsed or refractory Hodgkin's lymphoma in combination…

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “Safety and effectiveness in children have not been established.”

    US prescribing information · 2df937ad-a458-4030-bb7b-4468baa3685e · read 2026-08-30

  • On older people, the label states: “Clinical studies of carmustine for injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”

    US prescribing information · 2df937ad-a458-4030-bb7b-4468baa3685e · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary Carmustine for injection can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see Clinical Pharmacology (12.1) ] and findings in animals [see Data] .”

    US prescribing information · 2df937ad-a458-4030-bb7b-4468baa3685e · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of carmustine in human milk, the effects on the breastfed infant, or the effects on milk production.”

    US prescribing information · 2df937ad-a458-4030-bb7b-4468baa3685e · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Given by a clinician

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Intravenous

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S1, S3, S4, S6.

No source is stored against this line.

What is in the pack

Sold as powder, injectable, implant, wafer, given by the intravenous, injection, intracranial route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Intravenous

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 14 products list this as an active ingredient in the United States drug directory. 14 of them contain it and nothing else.

    FDA National Drug Code directory · 57821-002 · read 2026-08-29

  • They are sold as injection, powder, lyophilized, for solution, powder and wafer, taken intracavitary.

    FDA National Drug Code directory · 57821-002 · read 2026-08-29

  • The regulator's established pharmacologic class for it is alkylating activity [moa] and alkylating drug [epc].

    FDA National Drug Code directory · 57821-002 · read 2026-08-29

  • 14 published labels name it as an active ingredient. 14 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 2df937ad-a458-4030-bb7b-4468baa3685e · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 2df937ad-a458-4030-bb7b-4468baa3685e · read 2026-08-29

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Carmustine studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Carmustine are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
U68WG3173Y
RxNorm concept
212994

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S1, S3, S4, S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 14 approved applications cover products containing this substance. The earliest was NDA017422, approved 19770307 to AVET LIFESCIENCES.

    Drugs@FDA application register · NDA017422 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA017422 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19720101.

    FDA National Drug Code directory · 57821-002 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (10)

On the Carmustine label: indicated for what?

"Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors ( 1 )…": indications and usage on Carmustine's label. DailyMed label · b9b47082-32ee-4abb-a7b2-52292894d3f8 · 2026-04-09

194 registered trials of Carmustine — at which phases?

Registered studies posting no result
143 of 194

194 registered studies of Carmustine: 123 phase2, 47 phase1, 35 phase3, 9 na. CLINICALTRIALS_SNAPSHOT · 2026-09-01

413 with a PubMed record

Show the evidence
  • phase2
    123
  • phase1
    47
  • phase3
    35
  • na
    9
  • completed
    120
  • unknown
    25
4 more recorded rows
  • terminated
    23
  • recruiting
    10
  • withdrawn
    10
  • active not recruiting
    6

recorded 2026-09-01 · last checked 2026-09-04

29 of Carmustine's trials stopped: safety, accrual/recruitment, funding/business, sponsor decision unspecified, other?

safety (2), accrual/recruitment (15), funding/business (4), sponsor decision unspecified (1) and other (7): Carmustine's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"poor accrual"; 29 of 194 registered studies

Show the evidence

Trial

  • NCT00002772
    terminated; "poor accrual"
  • NCT00003567
    terminated; "slow accrual"
  • NCT00005090
    terminated; "poor accrual"
  • NCT00005987
    terminated; "Withdrawn because treatment guidelines changed"
  • NCT00005998
    withdrawn; "Withdrawn because study never enrolled patients"
  • NCT00006123
    withdrawn; "Never started"
14 further recorded trials
  • NCT00481832
    terminated; "Accrual Factor"
  • NCT00482053
    terminated; "Low accrual"
  • NCT00505921
    terminated; "Slow Accrual."
  • NCT00632827
    terminated; "Manufacturing shortage of both Diftitox and Doxil"
  • NCT00669669
    terminated; "Terminated due to loss in funding."
  • NCT00723658
    withdrawn; "lack of accrual"
  • NCT00761280
    terminated; "Unable to recruit the projected patient number. All analyses are descriptive, only."
  • NCT00920153
    terminated; "Other new drugs"
  • NCT01186406
    terminated; "Study ended early due to toxicity"
  • NCT01220297
    terminated; "Low accrual"
  • NCT01500161
    terminated; "Insufficient accruals"
  • NCT01653418
    terminated; "Due to the high rate of morbidity and mortality"
  • NCT01692691
    terminated; "PI decision"
  • NCT02343666
    withdrawn; "Administrative closure prior to any enrollments"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Carmustine used Carmustine 7.7Mg Wafer — over how long?

studies of Carmustine used the recorded amount. ClinicalTrials.gov · 2026-09-01

1 recorded entry; human; also "Carmustine 7.7Mg Wafer"

Show the evidence
  • human NCT04222062
    Carmustine 7.7Mg Wafer

recorded 2026-09-01 · last checked 2026-09-04

Carmustine's half-life is 15 minutes — which schedules were studied?

15 minutes, the half-life Carmustine's label states: "Elimination Following a short intravenous infusion, the reported elimination half-life ranges from 15 minutes to 75 minutes." DailyMed label · b9b47082-32ee-4abb-a7b2-52292894d3f8 · 2026-04-09

Show the evidence
  • half life pharmacokinetics
    15 minutes; Elimination Following a short intravenous infusion, the reported elimination half-life ranges from 15 minutes to 75 minutes.
  • metabolism pharmacokinetics
    Metabolism Carmustine may be inactivated through denitrosation reactions catalyzed by both cytosolic and microsomal enzymes, including NADPH and glutathione-S-transferase.

recorded 2026-04-09 · last checked 2026-09-04

Which running trial of Carmustine could settle lifespan?

NCT02443077 measures 24-month Progression-free Survival (PFS), Defined as the Proportion of Patients Who Are Alive and Progression-free 2 Years From Randomization, reading out 2026-12-23.

5 open trials; n 94; "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma"

Show the evidence

Trial

  • NCT02443077
    "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma"; n 94; "24-month Progression-free Survival (PFS), Defined as the Proportion of Patients Who Are Alive and Progression-free 2 Years From Randomization"; 2026-12-23
  • NCT03125642
    "Auto Stem Cell Transplant for Lymphoma Patients"; n 150; "Progression Free Survival Comparison"; 2027-04-30
  • NCT01511562
    "Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma"; n 113; "Progression Free Survival"; 2027-05-02
  • NCT06377540
    "MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma"; n 28; "Progression free survival (PFS)"; 2027-09-01
  • NCT04871607
    "Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma"; n 33; "Progression free survival"; 2029-10-02

Which 70 trials of Carmustine posted no result?

Posted no result
70 of 70 completed trials
Registrations
NCT00002461, NCT00004688, NCT00003400, NCT00003348, NCT00002988 and NCT00003413, and 64 more
Completion dates
oldest 1991-07; newest 2024-05-31
Show the evidence

Trial

  • NCT00002461
    1991-07
  • NCT00004688
    1998-07
  • NCT00003400
    2000-03
  • NCT00003348
    2000-08
  • NCT00002988
    2000-11
  • NCT00003413
    2001-02
14 further recorded trials
  • NCT00005081
    2001-04
  • NCT00003463
    2002-07
  • NCT00003543
    2002-08
  • NCT00003399
    2002-09
  • NCT00003401
    2002-09
  • NCT00005066
    2002-10
  • NCT03722355
    2002-10-18
  • NCT00003397
    2002-12
  • NCT00003402
    2002-12
  • NCT00003346
    2003-02
  • NCT00006747
    2003-02
  • NCT00002552
    2003-10
  • NCT00005981
    2003-11
  • NCT00003176
    2004-01-06

At the median, Carmustine's trials enrolled 41 people — anything larger?

Median enrolment
41
Largest enrolment
1000
Registered trials counted
183

What do 919 spontaneous reports say about Carmustine — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Carmustine appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 919 reaction mentions were counted: febrile neutropenia 172; myelodysplastic syndrome 132; thrombocytopenia 104; mucosal inflammation 97. FAERS via Open Targets · CHEMBL513 · 2026-06-24

Show the evidence
  • febrile neutropenia
    172
  • myelodysplastic syndrome
    132
  • thrombocytopenia
    104
  • mucosal inflammation
    97
  • brain oedema
    95
  • pyrexia
    91
4 more recorded rows
  • pneumonitis
    64
  • neutropenia
    63
  • haematotoxicity
    52
  • venoocclusive liver disease
    49

recorded 2026-06-24 · last checked 2026-09-04

Which 10 reactions does Carmustine's label not list?

brain oedema, febrile neutropenia and haematotoxicity and 7 more reported for Carmustine, absent from its label. FAERS via Open Targets · CHEMBL513 · 2026-06-24

2 label terms; 10 reported and unlisted; b9b47082-32ee-4abb-a7b2-52292894d3f8

Show the evidence
  • brain oedema
    count not stated
  • febrile neutropenia
    count not stated
  • haematotoxicity
    count not stated
  • mucosal inflammation
    count not stated
  • myelodysplastic syndrome
    count not stated
  • neutropenia
    count not stated
4 more recorded rows
  • pneumonitis
    count not stated
  • pyrexia
    count not stated
  • thrombocytopenia
    count not stated
  • venoocclusive liver disease
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL513
PubChem CID
2578
CAS number
154-93-8
RxCUI
2105
InChIKey
DLGOEMSEDOSKAD-UHFFFAOYSA-N
Development code
BCNU, DTI-015, FDA-0345, NSC-409962, SK-27702, SRI-1720
Also called
Becenun, Bischloroethyl nitrosourea, Camustine, Carmubris, Carmustina, carmustine sustained release implant, casant, gliadel wafer, gliadel wafers, BISCHLOROETHYL NITROSOUREA [IARC], CAMUSTINE [VANDF], CARMUSTINE [EP IMPURITY]
Trade name
Bicnu, Carmustine medac (previously carmustine obvius), Carmustine obvius, Gliadel, Gliadel / Bicnu
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.